ANGLE hails 'groundbreaking' research that underlines the potential of its liquid biopsy system in metastatic breast cancer

ANGLE PLC (AIM:AGL, OTCQX:ANPCY)’s liquid biopsy system could offer an alternative to traditional tissue biopsy to assess the spread and mutation of metastatic breast cancer.

The company described as ‘ground-breaking’ research by the University of Southern California Norris Cancer Center that compared the two approaches.

Not only did they find a ‘concordance’, or consistency between blood and tissue samples taken from patients when analysed, the scientists were also able to glean additional crucial detail from circulating tumour cells harvested using ANGLE’s Parsortix system.

Specifically, Parsortix enabled longitudinal analysis of the cancer cells as they metastasised (spread from the original site) and mutated. Dr Julie Lang and her team at USC were even able to detect the changes that lead to resistance to anti-cancer therapies.

This is important as it could help optimise the treatment given to women with metastatic breast cancer.

It is also important to note that only 50% of people with the advanced form of the disease have successful tissue biopsies as they are either too ill to undergo the invasive procedure or the tissue site is inaccessible.

So, as ANGLE pointed out in its press release: “A simple, repeatable liquid biopsy alternative using the Parsortix system could resolve the issues with metastatic tissue biopsies and, as the study finds, provide real time information on the cancer evolution to guide treatment options.”

Story by ProactiveInvestors